Vol.

No.

June 28, 2024Jun 28, 2024

DOWNLOAD THE PDF

Cover Story

High school science competitions shaped the careers of Regeneron’s co-founders—now, they’re paying it forward

NCI’s Youth Enjoy Science (YES) program also invests in student scientists

By McKenzie Prillaman

Kate Choi grew up hearing conversations about skin cancer. Her grandparents had it, as did her cousins.

Clinical

NCI’s Virtual Clinical Trials Office fills the staffing shortages at cancer centers

By Matthew Bin Han Ong

White House

At White House forum, Bertagnolli, Califf, Wegrzyn call for greater innovation in clinical trials

By McKenzie Prillaman

Free Obituary

Edward Sondik, electrical engineer turned public health expert and one-time interim NCI director, dies at 82

By Jacquelyn Cobb

BSA approves five new, 17 reissue concepts

By McKenzie Prillaman

Free In the Archives

Edward Sondik on his beginnings in public health, cancer prevention, and a “battlefield promotion”

In Brief

MD Anderson, Rice form Cancer Bioengineering Collaborative

If you like big houses and have $34.9M to spend, ACS has a house for you

Vivek Kavadi named CEO of American Society for Radiation Oncology

Miguel Villalona Calero named deputy director of UC Irvine Chao Family CCC

Steinhart, Foisey, Ganguly, Yamada-Hunter receive PICI Early Career Researcher awards

Noam Auslander receives $600K grant to identify connections between gut microbial genes and melanoma immunotherapy

UAMS Winthrop P. Rockefeller Cancer Institute receives five NCI grants

Fred Hutch establishes scientific training program for high school and middle school teachers

Clinical Roundup

FDA guidance provides new details on diversity action plans for clinical studies

Pan-cancer proteogenomics reveals potential drug targets

Upregulating TERT gene expression reverses multiple hallmarks of aging

CHK1 inhibitor + rheumatoid arthritis drug could be therapy for NSCLC

Tai Chi reduces risk of inflammatory disease, treats insomnia among breast cancer survivors

Starpax announces magnetic field-controlled bacteria that deliver drugs to solid tumors

Drugs & Targets

FDA approves Epkinly for R/R follicular lymphoma

EC approves Fruzaqla for previously-treated mCRC

eHealth Technologies, CancerX collaborate to accelerate cancer innovation in U.S.

Merck, Qure.ai collaborate to expand lung cancer detection via AI

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 51 | Issue 32 - September 05, 2025

High school science competitions shaped the careers of Regeneron’s co-founders—now, they’re paying it forward

NCI’s Virtual Clinical Trials Office fills the staffing shortages at cancer centers

At White House forum, Bertagnolli, Califf, Wegrzyn call for greater innovation in clinical trials

Edward Sondik, electrical engineer turned public health expert and one-time interim NCI director, dies at 82

BSA approves five new, 17 reissue concepts

Edward Sondik on his beginnings in public health, cancer prevention, and a “battlefield promotion”

In Brief

MD Anderson, Rice form Cancer Bioengineering Collaborative

If you like big houses and have $34.9M to spend, ACS has a house for you

Vivek Kavadi named CEO of American Society for Radiation Oncology

Miguel Villalona Calero named deputy director of UC Irvine Chao Family CCC

Steinhart, Foisey, Ganguly, Yamada-Hunter receive PICI Early Career Researcher awards

Noam Auslander receives $600K grant to identify connections between gut microbial genes and melanoma immunotherapy

UAMS Winthrop P. Rockefeller Cancer Institute receives five NCI grants

Fred Hutch establishes scientific training program for high school and middle school teachers

Clinical Roundup

FDA guidance provides new details on diversity action plans for clinical studies

Pan-cancer proteogenomics reveals potential drug targets

Upregulating TERT gene expression reverses multiple hallmarks of aging

CHK1 inhibitor + rheumatoid arthritis drug could be therapy for NSCLC

Tai Chi reduces risk of inflammatory disease, treats insomnia among breast cancer survivors

Starpax announces magnetic field-controlled bacteria that deliver drugs to solid tumors

Drugs & Targets

FDA approves Epkinly for R/R follicular lymphoma

EC approves Fruzaqla for previously-treated mCRC

eHealth Technologies, CancerX collaborate to accelerate cancer innovation in U.S.

Merck, Qure.ai collaborate to expand lung cancer detection via AI

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login